Formate promotes invasion and metastasis in reliance on lipid metabolism.

CP: Cancer CP: Metabolism cancer metastasis formate overflow invasion one-carbon metabolism

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
26 09 2023
Historique:
received: 29 04 2022
revised: 09 05 2023
accepted: 11 08 2023
medline: 5 10 2023
pubmed: 31 8 2023
entrez: 31 8 2023
Statut: ppublish

Résumé

Metabolic rewiring is essential for cancer onset and progression. We previously showed that one-carbon metabolism-dependent formate production often exceeds the anabolic demand of cancer cells, resulting in formate overflow. Furthermore, we showed that increased extracellular formate concentrations promote the in vitro invasiveness of glioblastoma cells. Here, we substantiate these initial observations with ex vivo and in vivo experiments. We also show that exposure to exogeneous formate can prime cancer cells toward a pro-invasive phenotype leading to increased metastasis formation in vivo. Our results suggest that the increased local formate concentration within the tumor microenvironment can be one factor to promote metastases. Additionally, we describe a mechanistic interplay between formate-dependent increased invasiveness and adaptations of lipid metabolism and matrix metalloproteinase activity. Our findings consolidate the role of formate as pro-invasive metabolite and warrant further research to better understand the interplay between formate and lipid metabolism.

Identifiants

pubmed: 37651228
pii: S2211-1247(23)01045-8
doi: 10.1016/j.celrep.2023.113034
pii:
doi:

Substances chimiques

Formates 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

113034

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Catherine Delbrouck (C)

Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg; Faculty of Science, Technology and Medicine, University of Luxembourg, 2 avenue de Université, 4362 Esch-sur-Alzette, Luxembourg.

Nicole Kiweler (N)

Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.

Oleg Chen (O)

Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.

Vitaly I Pozdeev (VI)

Molecular Disease Mechanisms Group, Faculty of Science, Technology and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.

Lara Haase (L)

Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg; Faculty of Science, Technology and Medicine, University of Luxembourg, 2 avenue de Université, 4362 Esch-sur-Alzette, Luxembourg.

Laura Neises (L)

Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.

Anaïs Oudin (A)

NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.

Aymeric Fouquier d'Hérouël (A)

Integrative Cell Signaling Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.

Ruolin Shen (R)

Helmholtz AI Central Unit, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.

Lisa Schlicker (L)

Division of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Proteomics Core Facility, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Rashi Halder (R)

RNAseq Platform, Systems Ecology Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.

Antoine Lesur (A)

Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.

Anne Schuster (A)

NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.

Nadja I Lorenz (NI)

Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, 60528 Frankfurt am Main, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, 60590 Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany.

Christian Jaeger (C)

Metabolomics Platform, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.

Maureen Feucherolles (M)

Molecular and Thermal Analysis Group, Materials Research and Technology, Luxembourg Institute of Science and Technology, 4422 Belvaux, Luxembourg.

Gilles Frache (G)

Molecular and Thermal Analysis Group, Materials Research and Technology, Luxembourg Institute of Science and Technology, 4422 Belvaux, Luxembourg.

Martyna Szpakowska (M)

Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, 4354 Esch-sur-Alzette, Luxembourg.

Andy Chevigne (A)

Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health, 4354 Esch-sur-Alzette, Luxembourg.

Michael W Ronellenfitsch (MW)

Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, Goethe University, 60528 Frankfurt am Main, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, 60590 Frankfurt am Main, Germany; Frankfurt Cancer Institute (FCI), University Hospital Frankfurt, Goethe University, 60596 Frankfurt am Main, Germany; University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Goethe University, 60590 Frankfurt am Main, Germany.

Etienne Moussay (E)

Tumor-Stroma Interactions Group, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.

Marie Piraud (M)

Helmholtz AI Central Unit, Helmholtz Zentrum München, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.

Alexander Skupin (A)

Integrative Cell Signaling Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg; Department of Neurosciences, University of California San Diego, La Jolla, CA 92092, USA; Department of Physics and Material Science, University of Luxembourg, 1511 Luxembourg, Luxembourg.

Almut Schulze (A)

Division of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Simone P Niclou (SP)

Faculty of Science, Technology and Medicine, University of Luxembourg, 2 avenue de Université, 4362 Esch-sur-Alzette, Luxembourg; NORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.

Elisabeth Letellier (E)

Molecular Disease Mechanisms Group, Faculty of Science, Technology and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.

Johannes Meiser (J)

Cancer Metabolism Group, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg. Electronic address: johannes.meiser@lih.lu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH